Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska! Read the … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, won the first ever Excellence in Patient Centricity Award from the Society for Clinical Research Sites (SCRS). The award was presented to Meridian at the 2021 Global Site Solutions Summit in Hollywood, FL. Sponsored by … Read more
Officials from the U.S. Department of Health and Human Services (HHS) visited with leaders from Meridian Clinical Research (now part of Velocity Clinical Research) in Savannah, GA. Following a tour of the company’s internal medicine site in Savannah, the group held a roundtable to discuss … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. The company was also part of Platinum Research Network, which won the ViE award for Best Clinical Trial Network. “It’s incredible to … Read more
Brandon Essink, MD, CPI, is a co-principal investigator for the Phase 3 clinical trial of Moderna’s COVID-19 vaccine. Read the full National Institutes of Health (NIH) press release: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
The first participant in the Moderna Phase 3 COVID-19 vaccine trial was enrolled this morning by Dr. Paul Bradley, Principal Investigator at Meridian’s (now Velcoity Clinical Research) internal medicine site in Savannah, GA. Compliments to Moderna on this significant milestone for its mRNA vaccine … Read more
The first participant in the Moderna Phase 2 COVID-19 vaccine trial was enrolled this morning by Keith Vrbicky, MD, Meridian (now Velocity Clinical Research) Principal Investigator in Norfolk, NE. Congratulations to Moderna for making remarkable progress on its mRNA vaccine against novel coronavirus. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase
Bounphone Chanthavong (Willow), MPH, CCRC, is the 2019 PharmaTimes Clinical Research Coordinator of the Year! Willow is a research coordinator at Meridian’s (now Velocity Clinical Research) neurology site in Savannah, GA, and won the award on May 4, 2019, after a three-stage competition involving an initial … Read more
Results from clinical trials performed at Meridian Clinical Research (now Velocity Clinical Research) sites in Norfolk, NE, Omaha, NE, and Savannah, GA, were recently published in two prestigious medical journals. Brandon Essink, MD, CPI, co-authored an article published in Vaccine. Dr. Essink led a study … Read more
Brandon Essink, MD, CPI, co-authored an article recently published in the prestigious journal, Vaccine. A successful meningococcal disease vaccine trial led to this publication, which you can read now at: https://www.sciencedirect.com/science/article/pii/S0264410X18309460?via%3Dihub Title: Breadth of Coverage Against a Panel of 110 Invasive Disease Isolates, Immunogenicity … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.